SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Atsena Reports Preclinical ATSN-301 Data for Usher Syndrome

Atsena Therapeutics reports preclinical data showing MYO7A expression and favorable safety for its dual AAV gene therapy ATSN-301.

ATSENA

Related stories